Free Trial
NASDAQ:AVBP

ArriVent BioPharma (AVBP) Stock Price, News & Analysis

ArriVent BioPharma logo
$21.87 +0.24 (+1.11%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$21.28 -0.59 (-2.69%)
As of 07/14/2025 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ArriVent BioPharma Stock (NASDAQ:AVBP)

Key Stats

Today's Range
$21.58
$22.39
50-Day Range
$18.75
$25.42
52-Week Range
$15.47
$36.37
Volume
223,951 shs
Average Volume
231,548 shs
Market Capitalization
$748.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.29
Consensus Rating
Buy

Company Overview

ArriVent BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

AVBP MarketRank™: 

ArriVent BioPharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 678th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ArriVent BioPharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about ArriVent BioPharma's stock forecast and price target.
  • Earnings Growth

    Earnings for ArriVent BioPharma are expected to decrease in the coming year, from ($2.74) to ($3.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ArriVent BioPharma is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ArriVent BioPharma is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ArriVent BioPharma has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ArriVent BioPharma's valuation and earnings.
  • Percentage of Shares Shorted

    27.03% of the float of ArriVent BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ArriVent BioPharma has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ArriVent BioPharma has recently increased by 12.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ArriVent BioPharma does not currently pay a dividend.

  • Dividend Growth

    ArriVent BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.03% of the float of ArriVent BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ArriVent BioPharma has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ArriVent BioPharma has recently increased by 12.15%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ArriVent BioPharma has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for ArriVent BioPharma this week, compared to 3 articles on an average week.
  • Search Interest

    1 people have searched for AVBP on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.58% of the stock of ArriVent BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.48% of the stock of ArriVent BioPharma is held by institutions.

  • Read more about ArriVent BioPharma's insider trading history.
Receive AVBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AVBP Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Headlines

AVBP Stock Analysis - Frequently Asked Questions

ArriVent BioPharma's stock was trading at $26.64 at the beginning of the year. Since then, AVBP stock has decreased by 17.9% and is now trading at $21.87.

ArriVent BioPharma, Inc. (NASDAQ:AVBP) posted its quarterly earnings results on Monday, May, 12th. The company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $1.24.

ArriVent BioPharma (AVBP) raised $175 million in an initial public offering (IPO) on Friday, January 26th 2024. The company issued 9,722,222 shares at $18.00 per share.

Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/12/2025
Today
7/14/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVBP
Previous Symbol
NASDAQ:AVBP
CIK
1868279
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$45.00
Low Price Target
$33.00
Potential Upside/Downside
+79.6%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.49 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.21%
Return on Assets
-46.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.34
Quick Ratio
14.34

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.65 per share
Price / Book
2.86

Miscellaneous

Outstanding Shares
34,213,000
Free Float
27,856,000
Market Cap
$748.24 million
Optionable
N/A
Beta
1.20
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AVBP) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners